Abstract TP302: Life After Thrombectomy
Rattachement africain : us, in, bd. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background: Multiple randomized clinical trials have shown the benefits of thrombectomy in the treatment of acute stroke after 90 days; a recent study showed extended benefit in the functional outcomes of the original cohort of randomized patients. However, data on real-world experience on long-term outcomes, including recurrent vascular events and risk factor controls, is lacking. Aim: To study long-term clinical outcomes, risk factor modification, medication compliance, and recurrent events in patients undergoing thrombectomy in a community-based setting. Methods: Retrospective data was collected on 143 cases performed between 2013 and 2017 in a non-academic medical center. Long-term follow-up was performed by reviewing hospital and clinic records of available patients. Results: At the time of discharge, 79% of the 143 thrombectomy patients survived, 11% had died, and 10% went to hospice. Post-hospitalization data, ranging from 30-days to 3 years, was available in 83 patients. A majority of the survivors (81%) were living with family at home. Within that time frame, cardiovascular events occurred in 39% of patients, with 5 deaths (6%). Only 7% (6/83) of patients had a recurrent stroke; most of them were lacunar. Two patients had repeat thrombectomies, and one was treated with IV tpa. Seventy-nine percent (66/83) continued to be on anti-platelet agents. A surprising number (34/83) of long-term survivors continued to smoke and drink heavily (20/83). Only 78% of patients had regular medical care. Twenty-percent of survivors were depressed and 20% were demented. Conclusions: Although thrombectomy helps reduce disability and benefits stroke survival, there is a high incidence of cardiovascular and cerebrovascular events afterwards, due to poor control of risk factors, inadequate medical follow-up, and lack of lifestyle changes. Thrombectomy is a costly procedure; to be cost-effective in the long-term, it is imperative that the survivors are not left without proper medical surveillance and secondary prevention strategies.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Abstract TP302: Life After Thrombectomy
- Date Crossref
- 22/01/2018
- Éditeur
- Ovid Technologies (Wolters Kluwer Health)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Health First pays non établi dans la noticeÉtablissement de santé
-
Vikram Hospital pays non établi dans la noticeÉtablissement de santé
-
Johns Hopkins University pays non établi dans la noticeUniversité ou école supérieure
-
Holmes Regional Medical Center pays non établi dans la noticeÉtablissement de santé
-
Bangladesh Air Force Shaheen College pays non établi dans la noticeUniversité ou école supérieure
-
Bhuvaneswari K Dandapani pays non établi dans la noticeInstitution
-
Kai Bartolone pays non établi dans la noticeInstitution
-
Hari G Dandapani pays non établi dans la noticeInstitution
-
Logan Drewberry-Reeves pays non établi dans la noticeInstitution
-
Vikram Roy pays non établi dans la noticeInstitution
-
Nikila B Dandapani pays non établi dans la noticeInstitution
-
Holmes Regional Med Cntr pays non établi dans la noticeInstitution
Health First, Vikram Hospital et Johns Hopkins University, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.